These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
16. Adenovirus vector-mediated delivery of the prodrug-converting enzyme carboxypeptidase G2 in a secreted or GPI-anchored form: High-level expression of this active conditional cytotoxic enzyme at the plasma membrane. Cowen RL; Williams JC; Emery S; Blakey D; Darling JL; Lowenstein PR; Castro MG Cancer Gene Ther; 2002 Nov; 9(11):897-907. PubMed ID: 12386828 [TBL] [Abstract][Full Text] [Related]
17. Systemic gene-directed enzyme prodrug therapy of hepatocellular carcinoma using a targeted adenovirus armed with carboxypeptidase G2. Schepelmann S; Hallenbeck P; Ogilvie LM; Hedley D; Friedlos F; Martin J; Scanlon I; Hay C; Hawkins LK; Marais R; Springer CJ Cancer Res; 2005 Jun; 65(12):5003-8. PubMed ID: 15958540 [TBL] [Abstract][Full Text] [Related]
18. Anti-tumour effects of an antibody-carboxypeptidase G2 conjugate in combination with phenol mustard prodrugs. Blakey DC; Davies DH; Dowell RI; East SJ; Burke PJ; Sharma SK; Springer CJ; Mauger AB; Melton RG Br J Cancer; 1995 Nov; 72(5):1083-8. PubMed ID: 7577451 [TBL] [Abstract][Full Text] [Related]
19. Antibody-directed enzyme prodrug therapy: pharmacokinetics and plasma levels of prodrug and drug in a phase I clinical trial. Martin J; Stribbling SM; Poon GK; Begent RH; Napier M; Sharma SK; Springer CJ Cancer Chemother Pharmacol; 1997; 40(3):189-201. PubMed ID: 9219501 [TBL] [Abstract][Full Text] [Related]